Kaiser reports on quality of life outcomes after first-line treatment for prostate cancer

Kaiser Permanente maintains a large data registry in  order to assess the quality of outcomes over time among tens of thousands of Kaiser patients, prostate cancer patients included. … READ MORE …

Listen to Dr. Schellhammer discussing “Living well with prostate cancer”

Yesterday evening we were able to spend an hour talking with Dr. Paul Schellhammer — a prostate cancer patient and also a widely recognized prostate cancer specialist — about issues related to quality of life  and “living well” after diagnosis and treatment for prostate cancer over time. The recording of this conversation is now available on line on the CureTalks web site. … READ MORE …

Outcomes, side effects, quality of life, and choosing a treatment that works FOR YOU!

Three articles in this week’s Journal of the American Medical Association throw a little more light on issues related to quality of life after diagnosis and treatment for localized prostate cancer … but quite how much light it is difficult to tell. … READ MORE …

Wotz goin’ on in Canada? And wotz “True Nth”?

So apparently Prostate Cancer Canada has been working (rather secretively) on a series of projects under the umbrella name of their “True Nth” initiative. But it’s a little difficult to work out quite what is encompassed by this initiative, which has been funded (at least in part) by Movember. … READ MORE …

SBRT vs. moderate hypofractionation: same or better quality of life?

In several randomized clinical trials of external beam treatment of primary prostate cancer, we have seen that moderately hypofractionated intensity-modulated radiation therapy (HypoIMRT), accomplished in 12 to 26 treatments or fractions, is no worse than conventionally fractionated IMRT treatment (in 40 to 44 fractions). … READ MORE …

Outcomes, survival, and HRQOL in trials of new drugs (and what they mean in practice)

A new paper in the journal Quality of Life Research has raised the question of whether it is possible to use available quality of life data from Phase III trials of new drugs in the treatment of advanced prostate cancer to make rational decisions about the use of those drugs in clinical practice. … READ MORE …

Active surveillance in practice: probably not good enough as yet

As we have noted more than once before, a major problem with being managed on active surveillance is (potentially) whether one’s clinical management team really has been trained to conduct active surveillance in a sufficiently active manner. … READ MORE …